- Home
- IMUX vs RAND Comparison
IMUX vs RAND Comparison
Compare IMUX & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- RAND
- Stock Information
- Founded
- IMUX 2016
- RAND 1969
- Country
- IMUX United States
- RAND United States
- Employees
- IMUX N/A
- RAND N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- RAND Finance: Consumer Services
- Sector
- IMUX Health Care
- RAND Finance
- Exchange
- IMUX Nasdaq
- RAND Nasdaq
- Market Cap
- IMUX 67.8M
- RAND 57.6M
- IPO Year
- IMUX N/A
- RAND N/A
- Fundamental
- Price
- IMUX $0.81
- RAND $16.51
- Analyst Decision
- IMUX Strong Buy
- RAND
- Analyst Count
- IMUX 6
- RAND 0
- Target Price
- IMUX $11.60
- RAND N/A
- AVG Volume (30 Days)
- IMUX 1.8M
- RAND 5.0K
- Earning Date
- IMUX 08-07-2025
- RAND 08-05-2025
- Dividend Yield
- IMUX N/A
- RAND 10.11%
- EPS Growth
- IMUX N/A
- RAND 39.77
- EPS
- IMUX N/A
- RAND 3.12
- Revenue
- IMUX N/A
- RAND $8,499,970.00
- Revenue This Year
- IMUX N/A
- RAND N/A
- Revenue Next Year
- IMUX N/A
- RAND N/A
- P/E Ratio
- IMUX N/A
- RAND $5.23
- Revenue Growth
- IMUX N/A
- RAND 12.52
- 52 Week Low
- IMUX $0.56
- RAND $14.30
- 52 Week High
- IMUX $2.11
- RAND $31.89
- Technical
- Relative Strength Index (RSI)
- IMUX 54.61
- RAND 60.63
- Support Level
- IMUX $0.68
- RAND $16.26
- Resistance Level
- IMUX $0.83
- RAND $16.89
- Average True Range (ATR)
- IMUX 0.05
- RAND 0.41
- MACD
- IMUX 0.02
- RAND 0.21
- Stochastic Oscillator
- IMUX 89.29
- RAND 88.36
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.